NASDAQ:EDIT - Editas Medicine Stock Price, Forecast & News

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine Inc (NASDAQ:EDIT) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.66) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.73) by $0.07. The company earned $3.90 million during the quarter, compared to analyst estimates of $4.72 million. Editas Medicine had a negative net margin of 842.47% and a negative return on equity of 56.53%. The business's revenue for the quarter was down 73.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.32) EPS. View Editas Medicine's Earnings History.

Editas Medicine is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Editas Medicine.

5 brokerages have issued twelve-month target prices for Editas Medicine's shares. Their forecasts range from $29.00 to $55.00. On average, they anticipate Editas Medicine's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 30.6% from the stock's current price. View Analyst Price Targets for Editas Medicine.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine.

Headlines about EDIT stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Editas Medicine earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the near future. View News Stories for Editas Medicine.

Some companies that are related to Editas Medicine include argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and Denali Therapeutics (DNLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP), Advanced Micro Devices (AMD), Canopy Growth (CGC), TransEnterix (TRXC) and Baidu (BIDU).

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Global Thematic Partners LLC (0.82%), AE Wealth Management LLC (0.05%), Assenagon Asset Management S.A. (0.05%), Focused Wealth Management Inc (0.03%), Patriot Financial Group Insurance Agency LLC (0.01%) and Farmers & Merchants Trust Co of Chambersburg PA (0.01%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.

EDIT stock was sold by a variety of institutional investors in the last quarter, including Focused Wealth Management Inc. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Cynthia Collins and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.

EDIT stock was acquired by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Assenagon Asset Management S.A., AE Wealth Management LLC, Farmers & Merchants Trust Co of Chambersburg PA, Patriot Financial Group Insurance Agency LLC, Exchange Traded Concepts LLC and Endurance Wealth Management Inc.. View Insider Buying and Selling for Editas Medicine.

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EDIT stock can currently be purchased for approximately $29.10.

Editas Medicine has a market capitalization of $1.49 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.View Additional Information About Editas Medicine.

The official website for Editas Medicine is http://www.editasmedicine.com/.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]